Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib Maintenance Post Allogeneic HCT in IDH1-Mutated AML, MDS, or CMML
NCT06543381Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olutasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by City of Hope. Primary endpoints: Incidence of adverse events and Proportion of patients completing at least 6 months of study therapy. Started Dec 2024; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06543381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543381.